Portal de Periódicos da CAPES

On the Hispanic paradox in lung cancer

2024; Elsevier BV; Volume: 190; Linguagem: Inglês

10.1016/j.lungcan.2024.107537

1872-8332

John Rodriguez,

Lung Cancer Research Studies

We have read with interest Arrieta et al.'s publication [ [1] Arrieta O. Ramírez-Tirado L.A. Báez-Saldaña R. Peña-Curiel O. Soca-Chafre G. Macedo-Perez E.O. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer. 2015; 90: 161-166https://doi.org/10.1016/j.lungcan.2015.08.010 Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar ], reporting on the mutation profiles of Hispanic NSCLC that were consecutively treated at the thoracic oncology unit of the National Cancer Institute, Mexico, between 2007 and 2014. The results indicate that among 1260 patients, 340 had EGFR mutation (27 %). In a previous study, 2012 Arrieta et al. [ [2] Arrieta O. Campos-Parra A.D. Zuloaga C. Avilés A. Sánchez-Reyes R. Manríquez M.E. Covián-Molina E. Martínez-Barrera L. Meneses A. Cardona A. Borbolla-Escoboza J.R. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J. Thorac. Oncol. 2012; 7: 1228-1234https://doi.org/10.1097/JTO.0b013e3182582a93 Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar ] reported the results from years 2007–2010 on 914 patients. Though possible, it is pretty odd that 914 were treated from 2007 to 2010, but in the following 4-year period, the added number of patients was only 346 (for a total of 1260). In the 2012 report, Arrieta et al. presented inconsistencies throughout the publication in the number of patients with EGFR; the reported numbers were 113, 111,126 and 238 whose percentages varied from 30.4 % to 35.54 %.